1. Home
  2. LUNG vs ELUT Comparison

LUNG vs ELUT Comparison

Compare LUNG & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.27

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

ELUT

Elutia Inc.

HOLD

Current Price

$1.02

Market Cap

48.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUNG
ELUT
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.9M
48.3M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
LUNG
ELUT
Price
$1.27
$1.02
Analyst Decision
Buy
Strong Buy
Analyst Count
7
1
Target Price
$5.38
$6.00
AVG Volume (30 Days)
523.3K
121.9K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
7.64
146.77
EPS
N/A
0.87
Revenue
$90,497,000.00
$12,293,000.00
Revenue This Year
$2.48
N/A
Revenue Next Year
$18.46
$10.83
P/E Ratio
N/A
$1.21
Revenue Growth
8.01
N/A
52 Week Low
$1.13
$0.50
52 Week High
$3.88
$2.60

Technical Indicators

Market Signals
Indicator
LUNG
ELUT
Relative Strength Index (RSI) 45.03 44.52
Support Level $1.27 $1.00
Resistance Level $1.45 $1.18
Average True Range (ATR) 0.09 0.07
MACD 0.01 0.00
Stochastic Oscillator 35.19 31.82

Price Performance

Historical Comparison
LUNG
ELUT

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

About ELUT Elutia Inc.

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

Share on Social Networks: